HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
Stocks · News reference
FDA Approves Telix Pharma’s NDA For Pixclara, Amino Acid Positron Emission Tomography Drug For Imaging Gliomas
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell, but Radiant Logistics surged 17.8% after beating Q4 estimates. Waystar, Telix and Forgent also posted strong gains.
Telix Pharmaceuticals shares are trading higher after the company announced the FDA has approved its NDA for Pixclara, an amino acid positron emission tomography drug for imaging gliomas.
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
FDA approves Telix Pharmaceuticals' Pixclara, the first radiopharmaceutical brain cancer imaging drug for glioma PET scans.